Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection

作者：Jennifer Audsley, Anchalee Avihingsanon, Xin Li, Rosalind Edwards, Kathy Merlock Jackson, Nadia Warner, Olivia Maslac, Peter Revill, Hay Mar Su Lwin, Sivaporn Gatechompol, Nagalingeswaran Kumarasamy, Tim Spelman, Iskandar Azwa, Adeeba Kamarulzaman, Sharon R. Lewin, Joe Sasadeusz · 发表于：Clinical Infectious Diseases · 年份：2025 · DOI：10.1093/cid/ciaf281 · 被引用次数：6 · 研究领域：Hepatitis B Virus Studies、Hepatitis C virus research、HIV/AIDS drug development and treatment

BACKGROUND: An effective therapeutic strategy for hepatis B virus (HBV) cure remains an urgent unmet need. We aimed to define the incidence, kinetics, and predictors of hepatitis B surface antigen (HBsAg) loss in people with HIV and HBV (PWH-HBV) following HBV-active antiretroviral therapy (ART) in PWH-HBV in Asia. METHODS: 97 PWH-HBV commencing HBV-active ART were recruited prospectively in Thailand (n = 94) and Malaysia (n = 3), then followed for 24 months. Time to HBV serology change was calculated. Univariate associations between baseline characteristics and HBsAg loss were examined using the Mann-Whitney or chi-square tests. Multivariable analysis was undertaken using Cox regression. RESULTS: Twenty-one individuals (22%) lost HBsAg during follow-up (11.7 per 100 person-years), 14 of whom gained anti-HBs. Twenty-two of 61 (36.1%) individuals who were hepatitis B "e" antigen (HBeAg) positive at baseline lost HBeAg over the study, 15 of whom gained anti-HBe. Most individuals lost HBsAg and HBeAg by the month 12 study visit (81% and 63.6%, respectively), with median times of 5.8 and 12.0 months to HBsAg and HBeAg loss, respectively. Univariate analysis showed baseline characteristics associated with HBsAg loss were higher alanine aminotransferase (ALT; P = .005), tenofovir alafenamide (TAF)-containing ART regimen (P = .025), younger age (P = .040), lower liver stiffness (P = .010), and quantitative HBsAg < log10 2.0 IU/mL (P = .001). All 5 factors remained significant in a C...